| Literature DB >> 33222101 |
Matteo Paolucci1,2, Sara Biguzzi3, Francesco Cordici3, Enrico Maria Lotti4, Simonetta Morresi3, Michele Romoli3,4, Silvia Strumia5, Rossana Terlizzi3, Simone Vidale4, Maurizio Menarini6, Maria Ruggiero7, Alessandro Valentino8, Marco Longoni3,5.
Abstract
BACKGROUND: During the coronavirus disease 2019 (COVID-19) outbreak, a decrease of stroke's hospital admissions and reperfusion therapy has been reported worldwide. This retrospective observational study assessed the volume of stroke cases managed in the Emergency Department (ED) and reperfusion therapies in an Italian stroke network with a high incidence of COVID-19, particularly to evaluate if the in-hospital rerouting and the switch from a drip-and-ship to a mothership model could assure an adequate volume of acute treatments.Entities:
Keywords: COVID-19; SARS-CoV-2; Stroke incidence; Thrombectomy; Thrombolysis
Mesh:
Year: 2020 PMID: 33222101 PMCID: PMC7680213 DOI: 10.1007/s10072-020-04914-4
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.307
Fig. 1.Forlì-Cesena (FC—yellow) and Rimini (RN—red) provinces. “Morgagni-Pierantoni” hospital in Forlì and “Infermi” hospital in Rimini are the main Primary Stroke Centers (spokes) of the network; “M. Bufalini” hospital in Cesena is the Comprehensive Stroke Center (hub) of the stroke network. Green arrows: drip-and-ship model (light green arrows: primary transport to the spokes; dark green arrows: secondary transport to the hub). Blue arrows: mothership model (direct transportation to the hub), applied in the province of Rimini
Fig. 3Volumes of reperfusion therapies in March 2018, 2019, and 2020 in the stroke network
Suspected and confirmed stroke cases in ED in March 2019 and March 2020
| FC | RN | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ED stroke-codeb | Final stroke diagnosisc | ED stroke-codeb | Final stroke diagnosisc | ED stroke-codeb | Final stroke diagnosisc | ||||||||||
| Resident population | Absolute number | Incidence (/100,000) | Absolute number | Incidence (/100,000) | Resident population | Absolute number | Incidence (/100,000) | Absolute number | Incidence (/100,000) | Resident population | Absolute number | Incidence (/100,000) | Absolute number | Incidence (/100,000) | |
| March 2019 | 394475 | 145 | 36.76 | 116 | 29.41 | 339259 | 115 | 33.90 | 78 | 22.99 | 733734 | 260 | 35.44 | 194 | 26.44 |
| March 2020a | 394609 | 118 | 29.90 | 90 | 22.81 | 340125 | 102 | 29.99 | 49 | 14.41 | 734734 | 220 | 29.94 | 139 | 18.92 |
| % variation | − 19% | − 22% | − 11% | − 37% | − 15% | − 28% | |||||||||
| Incidence rate ratio | 1.23 (95% CI 0.96–1.58) | 1.29 (95% CI 0.97–1.71) | 1.13 (95% CI 0.86–1.48) | 1.60 (95% CI 1.11–2.30) | 1.18 (95% CI 0.99–1.42) | 1.40 (95% CI 1.12–1.75) | |||||||||
aResident population based on Nov 2019
bAllocated in each province by place of stroke onset
cAllocated in each province by place of hospital admission
Fig. 2.a Cumulative incidence of suspected stroke cases during March 2020 (blue) and March 2019 (orange) and cumulative incidence of COVID-19 cases in March 2020 (red dots). b Daily cases of suspected stroke cases during March 2020 (blue) and March 2019 (orange) and cumulative incidence of COVID-19 cases in March 2020 (red dots)
Performances of intravenous thrombolysis in FC province in March 2019 and March 2020. Noteworthy, in March 2020
| IVT no. | EVT no. | Combined treatment no. | Median call-to-needle time (min) | Median door-to-needle time (min) | |
|---|---|---|---|---|---|
| March 2019 | 11 | 2 | 4 | 108.5 (IQR 34) | 69 (IQR 41) |
| March 2020a | 10 | 2 | 3 | 96 (IQR 23) | 49 (IQR 37) |
| .126 | .142 |
aThree IVT, one EVT, and five combined treatments were carried out in Cesena but were excluded because they were transported from RN province due to the switch to a mothership model
Fig. 4Door-to-needle (DTN), call-to-needle (CTN), door-to-groin (DTG), and call-to-groin times in RN provinces. Red and blue bars represent drip-and-ship (D-a-S) treatments in, respectively, March 2019 and the first part of March 2020; yellow bars represent mothership (MS) treatments in March 2020.